MA32018B1 - Vaccin - Google Patents

Vaccin

Info

Publication number
MA32018B1
MA32018B1 MA33017A MA33017A MA32018B1 MA 32018 B1 MA32018 B1 MA 32018B1 MA 33017 A MA33017 A MA 33017A MA 33017 A MA33017 A MA 33017A MA 32018 B1 MA32018 B1 MA 32018B1
Authority
MA
Morocco
Prior art keywords
gag
hiv
immunogenic
cysteine
component
Prior art date
Application number
MA33017A
Other languages
Arabic (ar)
English (en)
Inventor
Dominique Ingrid Lemoine
Sophie Valerie Anne Ponsard
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA32018B1 publication Critical patent/MA32018B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Constituant de vaccin anti-vih comprenant: (a) une protéine de fusion immunogène comprenant nef ou son fragment immunogène ou son dérivé et p17 gag et/ou p24 gag ou leurs fragments immunogènes ou leurs dérivés, au moins un antigène ou un fragment immunogène de vih étant placé entre p17 et p24 gag, dans le cas de la présence de ces derniers; (b) un agent stabilisant sélectionné dans le groupe consistant en monothioglycérol, cystéine, n-acétyl cystéine ou leurs mélanges. L'invention concerne également des vaccins anti-vih contenant ledit constituant, ainsi que l'utilisation desdits vaccins pour la prophylaxie et le traitement du vih.
MA33017A 2007-12-21 2010-07-14 Vaccin MA32018B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1576707P 2007-12-21 2007-12-21
US1995108P 2008-01-09 2008-01-09
PCT/EP2008/067945 WO2009080719A1 (fr) 2007-12-21 2008-12-18 Vaccin

Publications (1)

Publication Number Publication Date
MA32018B1 true MA32018B1 (fr) 2011-01-03

Family

ID=40577907

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33017A MA32018B1 (fr) 2007-12-21 2010-07-14 Vaccin

Country Status (16)

Country Link
US (2) US20100285051A1 (fr)
EP (1) EP2247307A1 (fr)
JP (2) JP2011506565A (fr)
KR (1) KR20100109555A (fr)
CN (1) CN101951950A (fr)
AU (1) AU2008339984A1 (fr)
BR (1) BRPI0821555A2 (fr)
CA (1) CA2708718A1 (fr)
CO (1) CO6290701A2 (fr)
CR (1) CR11575A (fr)
DO (1) DOP2010000188A (fr)
EA (1) EA201000829A1 (fr)
IL (1) IL206307A0 (fr)
MA (1) MA32018B1 (fr)
WO (1) WO2009080719A1 (fr)
ZA (1) ZA201004303B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011026111A1 (fr) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale
ES2643498T3 (es) 2010-04-08 2017-11-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Ensayo de células presentadoras de antígenos de linfocitos B
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9676818B2 (en) 2013-01-17 2017-06-13 University Of Kansas Toll-like receptor 2-agonistic lipopeptides, and method of making the same
CN103330935A (zh) * 2013-06-17 2013-10-02 中山大学 果糖作为疫苗佐剂的应用
GB201318862D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
GB201318858D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
KR20180115276A (ko) 2016-02-22 2018-10-22 베링거잉겔하임베트메디카게엠베하 생체 분자의 고정화 방법
EP3773698A1 (fr) 2018-04-03 2021-02-17 Sanofi Protéines de ferritine
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
CN112512566A (zh) * 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
KR20210018205A (ko) 2018-04-03 2021-02-17 사노피 항원성 OspA 폴리펩타이드
EP3833382A1 (fr) * 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processus et vaccins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464474A (en) * 1980-07-09 1984-08-07 Connaught Laboratories Limited Non-A, non-B hepatitis assay and vaccine
AU2088992A (en) * 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
EP1100925B1 (fr) * 1998-07-31 2006-01-18 Akzo Nobel N.V. Virus herpetique equin attenue
AU2001286996A1 (en) * 2000-08-31 2002-03-13 Chiron Corporation Stabilized fgf formulations containing reducing agents
FR2813756B1 (fr) * 2000-09-11 2003-03-07 Imv Technologies Dilueur pour la conservation de spermatozoides de porcins
JP2005500336A (ja) * 2001-07-25 2005-01-06 ニューヨーク・ユニバーシティ 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用
JP2005525344A (ja) * 2002-02-04 2005-08-25 コリクサ コーポレイション アミノアルキルグルコサミニドホスフェートおよびサポニンを含む免疫刺激性組成物
US20030215455A1 (en) * 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
GB0300427D0 (en) * 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
WO2005074460A2 (fr) * 2003-12-05 2005-08-18 Becton Dickinson And Company Procedes pour ameliorer la reponse immunitaire dans une partie intradermique et composes utilises dans ces procedes
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity

Also Published As

Publication number Publication date
BRPI0821555A2 (pt) 2015-06-16
JP2011506565A (ja) 2011-03-03
CR11575A (es) 2010-09-29
ZA201004303B (en) 2011-11-30
DOP2010000188A (es) 2010-10-31
IL206307A0 (en) 2010-12-30
EP2247307A1 (fr) 2010-11-10
CA2708718A1 (fr) 2009-07-02
JP2015007067A (ja) 2015-01-15
WO2009080719A1 (fr) 2009-07-02
CO6290701A2 (es) 2011-06-20
EA201000829A1 (ru) 2011-06-30
KR20100109555A (ko) 2010-10-08
US20100285051A1 (en) 2010-11-11
US20140193481A1 (en) 2014-07-10
CN101951950A (zh) 2011-01-19
AU2008339984A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
NO20072733L (no) Doseformer
EA201000829A1 (ru) Вакцина
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20064584L (no) Tetrahydropyridoindolderivater
MA38567A1 (fr) Variantes de pertuzumab et leur évaluation
EA200001030A1 (ru) Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
NO20073764L (no) Sammensetninger for behandling av HCV
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
PE20070116A1 (es) Formulacion de anticuerpos estables
MX349481B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
BRPI0612656A8 (pt) composição imunogênica, vacina, kit de vacina para a administração concomitante ou sequencial, processo para a produção da vacina, método de imunização de um hospedeiro humano contra doença causada por infecção de neisseria meningitidis, e, uso da composição imunogênica
NO20070702L (no) Kombinasjonsbehandling for ikke-hematologisk malignitet ved anvendelse av anti-OGF-1R antistoff
AR080216A2 (es) Composiciones farmaceuticas que contienen una proteina de fusion de vih
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA30670B1 (fr) Vaccins contre le paludisme
MA42811B1 (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
PE20061372A1 (es) Composicion farmaceutica que contiene un vector adenovirus
BR0204470A (pt) Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos
PE20060149A1 (es) Formulacion farmaceutica para tratar la infeccion por vih
MA27699A1 (fr) Vaccin contre vhc
MA32030B1 (fr) Vaccins anti-malaria
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
NO20073071L (no) Benzotiazolformuleringer og anvendelse av disse
TR200102024T2 (tr) Yeni tedavi.